Medical staff conduct clinical trials with 3D printing and imaging technology
In terms of medical products , neither drugs nor devices have been market tested before clinical trials. Providing new medical products to the public is a long and expensive process, but several medical professionals in the United States have found that this process can be a bit easier thanks to Materialise. 3D printing and software company Materialise has a long history of assisting with medical procedures. Just a few days ago, Xiaobian learned about case studies involving complex jaw surgery. However, Materialise has proven to be a valuable partner for medical professionals before bringing patients into the operating room.
One challenge in clinical trials comes from how to choose the right patient group. However, Materialize's 3D imaging software is helping surgeons and medical device companies analyze and select the ideal patient for a particular trial based on their anatomy. Once the patient is selected, the physician and other medical professionals can create a separate 3D printed model based on each patient's anatomy to develop a treatment or surgical plan in advance.
3D printing also helps medical device manufacturers protosize products faster, cheaper, and more efficiently. The faster the device is completed, the faster it can enter clinical trials, and the final approval for general use, and Materialize has provided 3D printing services to many manufacturers developing new devices.
Bryan Crutchfield, vice president and general manager of Materialize North America, said: "At Materialize, we believe our mission is to create a better, healthier world. We work closely with hospitals and medical device companies to help explore opportunities for complex and innovative medical procedures. By partnering with partners to create more effective and efficient clinical trials using 3D printing, we are helping them bring innovative devices and procedures to market and improve patient care."
Recently, Materialize has partnered with Detroit's Henry Ford Health System to develop screening and planning solutions for patients with severe mitral valve disease. The standard of treatment for this disease is dangerous open surgery, but new treatments are under development involving the replacement of the mitral valve by a patient's vascular insertion device.
Lettuce
Jiangsu Tiankang Food Co., Ltd. , https://www.tiankangfood.com